KDR and cancer: The combined OR showed that the use of VEGFR-TKIs significantly increased the risk of high-grade proteinuria events among cancer patients (OR 1.97, 95%CI: 1.01–3.84, p = 0.046, figure 3) using a fixed effects model (I2 = 0%, p = 0.93).